Martina Sassone-Corsi, PhD

Associate Director, Research and Discovery
GentiBio
Cambridge, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• GNTI-932: A Targeted, Scalable, and Hypoimmune Allogeneic Engineered Treg therapy for the treatment of Inflammatory Bowel Disease.

  Thursday, April 16, 2026
  1:00 PM - 1:15 PM US ET